Reviva Pharmaceuticals is set to present positive speech latency data for its drug candidate, brilaroxazine, in the treatment of schizophrenia. The data comes from the Phase 3 RECOVER trial and will be shared at the CNS Summit 2024 in Boston, Massachusetts.
The presentation, titled 'Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine,' will be delivered as a poster presentation by Dr. Jan Sedway from WCG Clinical on November 12th. The study suggests that enriching the patient population based on speech latency enhances the treatment effects of brilaroxazine.
RECOVER Trial and Speech Latency
The RECOVER trial is a Phase 3 study designed to evaluate the efficacy and safety of brilaroxazine in patients with schizophrenia. Speech latency, the delay in responding to a question or prompt, is increasingly recognized as a potential biomarker for treatment response in schizophrenia.
Reviva Pharmaceuticals is a late-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory, and cardiometabolic diseases. Brilaroxazine (RP5063) and RP1208 are their primary drug candidates, both new chemical entities discovered in-house. The company holds composition of matter patents for both compounds in the United States, Europe, and other countries.
CNS Summit Presentation Details
The poster presentation will take place on Tuesday, November 12th, from 5:00 to 7:00 PM ET. Abstracts and additional details can be found on the CNS Summit 2024 website.
